Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 125
2021 249
2022 251
2023 134
2024 32

Text availability

Article attribute

Article type

Publication date

Search Results

709 results

Results by year

Filters applied: . Clear all
Page 1
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
Bramante CT, Huling JD, Tignanelli CJ, Buse JB, Liebovitz DM, Nicklas JM, Cohen K, Puskarich MA, Belani HK, Proper JL, Siegel LK, Klatt NR, Odde DJ, Luke DG, Anderson B, Karger AB, Ingraham NE, Hartman KM, Rao V, Hagen AA, Patel B, Fenno SL, Avula N, Reddy NV, Erickson SM, Lindberg S, Fricton R, Lee S, Zaman A, Saveraid HG, Tordsen WJ, Pullen MF, Biros M, Sherwood NE, Thompson JL, Boulware DR, Murray TA; COVID-OUT Trial Team. Bramante CT, et al. N Engl J Med. 2022 Aug 18;387(7):599-610. doi: 10.1056/NEJMoa2201662. N Engl J Med. 2022. PMID: 36070710 Free PMC article. Clinical Trial.
BACKGROUND: Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an important component of the comprehensive response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. METHODS: In this phase 3, dou …
BACKGROUND: Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an important component of the comprehensi …
Ivermectin in COVID-19: What do we know?
Pandey S, Pathak SK, Pandey A, Salunke AA, Chawla J, Sharma A, Sharma S, Thivari P, Ratna HVK. Pandey S, et al. Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1921-1922. doi: 10.1016/j.dsx.2020.09.027. Epub 2020 Sep 28. Diabetes Metab Syndr. 2020. PMID: 33032231 Free PMC article. Review. No abstract available.
Ivermectin in COVID-19 Management: What is the Current Evidence?
Eerike M, Raj GM, Priyadarshini R, Ravi G, Bisoi D, Konda VGR. Eerike M, et al. Infect Disord Drug Targets. 2022;22(4):e190122200367. doi: 10.2174/1871526522666220119114035. Infect Disord Drug Targets. 2022. PMID: 35043770 Review.
Some studies suggested that a higher dose or increased duration of ivermectin usage was required to achieve favorable effects. In this review, articles on the prophylactic role of ivermectin in COVID-19 are also discussed - wherein the results are more …
Some studies suggested that a higher dose or increased duration of ivermectin usage was required to achieve favorable effects. In thi …
Ivermectin for preventing and treating COVID-19.
Popp M, Reis S, Schießer S, Hausinger RI, Stegemann M, Metzendorf MI, Kranke P, Meybohm P, Skoetz N, Weibel S. Popp M, et al. Cochrane Database Syst Rev. 2022 Jun 21;6(6):CD015017. doi: 10.1002/14651858.CD015017.pub3. Cochrane Database Syst Rev. 2022. PMID: 35726131 Free PMC article. Review.
The molecular hypothesis of ivermectin's antiviral mode of action suggests an inhibitory effect on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in early stages of infection. Currently, evidence on ivermectin fo …
The molecular hypothesis of ivermectin's antiviral mode of action suggests an inhibitory effect on severe acute respiratory sy …
Ivermectin's Role in the Prevention of COVID-19: A Systematic Review and Meta-Analysis.
Hu GY, Liang CA, Lin PC, Lin CY. Hu GY, et al. J Clin Pharmacol. 2023 Mar;63(3):288-297. doi: 10.1002/jcph.2178. Epub 2022 Dec 10. J Clin Pharmacol. 2023. PMID: 36399336 Review.
Randomized controlled trials (RCTs) and cohort studies investigating ivermectin for coronavirus disease 2019 (COVID-19) prevention were included. ...In summary, prophylactic ivermectin did not prevent COVID-19 in the postexposure populati …
Randomized controlled trials (RCTs) and cohort studies investigating ivermectin for coronavirus disease 2019 (COVID-19) …
Ivermectin for COVID-19: The 2022 Update.
Manu P. Manu P. Am J Ther. 2022 Nov-Dec 01;29(6):e647-e648. doi: 10.1097/MJT.0000000000001577. Am J Ther. 2022. PMID: 36608065 No abstract available.
The use of Ivermectin for the treatment of COVID-19: Panacea or enigma?
Onyeaka H, Tamasiga P, Agbara JO, Mokgwathi OA, Uwishema O. Onyeaka H, et al. Clin Epidemiol Glob Health. 2022 Jul-Aug;16:101074. doi: 10.1016/j.cegh.2022.101074. Epub 2022 Jun 8. Clin Epidemiol Glob Health. 2022. PMID: 35694631 Free PMC article. Review.
To date, no treatments have been demonstrated to cure COVID-19. The scientific World is now considering the potential use of Ivermectin as a prophylactic and treatment for COVID-19. ...There are inconsistent results on the effectiveness of Iv …
To date, no treatments have been demonstrated to cure COVID-19. The scientific World is now considering the potential use of …
Repurposing the drug, ivermectin, in COVID-19: toxicological points of view.
Shirazi FM, Mirzaei R, Nakhaee S, Nejatian A, Ghafari S, Mehrpour O. Shirazi FM, et al. Eur J Med Res. 2022 Feb 5;27(1):21. doi: 10.1186/s40001-022-00645-8. Eur J Med Res. 2022. PMID: 35123559 Free PMC article. Review.
The most recommended dose of ivermectin for the treatment of COVID-19 is 150-200 g/kg twice daily. As ivermectin adoption for COVID-19 increased, the Food and Drug Administration (FDA) issued a warning on its use during the pandemic. ...
The most recommended dose of ivermectin for the treatment of COVID-19 is 150-200 g/kg twice daily. As ivermectin …
A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness.
Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, Rahman M, Zaman K, Somani J, Yasmin R, Hasnat MA, Kabir A, Aziz AB, Khan WA. Ahmed S, et al. Int J Infect Dis. 2021 Feb;103:214-216. doi: 10.1016/j.ijid.2020.11.191. Epub 2020 Dec 2. Int J Infect Dis. 2021. PMID: 33278625 Free PMC article. Clinical Trial.
Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. ...There were no severe adverse drug events recorded in the study. A 5- …
Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome c …
Unethical studies of ivermectin for covid-19.
Meyerowitz-Katz G, Wieten S, Medina Arellano MJ, Yamey G. Meyerowitz-Katz G, et al. BMJ. 2022 Apr 14;377:o917. doi: 10.1136/bmj.o917. BMJ. 2022. PMID: 35422425 No abstract available.
709 results